NASDAQ:SEPN - Nasdaq - US81734D1046 - Common Stock - Currency: USD
NASDAQ:SEPN (5/22/2025, 3:53:02 PM)
9.38
+0.32 (+3.53%)
The current stock price of SEPN is 9.38 USD. In the past month the price increased by 47.56%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 52.07 | 679.28B | ||
JNJ | JOHNSON & JOHNSON | 15.21 | 367.84B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 19.5 | 302.92B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.54 | 222.25B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 18.82 | 217.04B | ||
MRK | MERCK & CO. INC. | 10 | 196.09B | ||
PFE | PFIZER INC | 7.18 | 130.70B | ||
SNY | SANOFI-ADR | 13.66 | 128.45B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.41 | 95.81B | ||
GSK | GSK PLC-SPON ADR | 7.06 | 78.71B | ||
ZTS | ZOETIS INC | 26.99 | 72.48B | ||
HLN | HALEON PLC-ADR | 22.59 | 49.92B |
Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. The company is headquartered in South San Francisco, California and currently employs 75 full-time employees. The company went IPO on 2024-10-25. The firm is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. The company is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with unmet needs. The company is focused on therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.
SEPTERNA INC
250 East Grand Avenue, Suite 65
South San Francisco CALIFORNIA US
Employees: 75
Phone: 16503383533
The current stock price of SEPN is 9.38 USD. The price increased by 3.53% in the last trading session.
The exchange symbol of SEPTERNA INC is SEPN and it is listed on the Nasdaq exchange.
SEPN stock is listed on the Nasdaq exchange.
10 analysts have analysed SEPN and the average price target is 15.81 USD. This implies a price increase of 68.55% is expected in the next year compared to the current price of 9.38. Check the SEPTERNA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
SEPTERNA INC (SEPN) has a market capitalization of 413.66M USD. This makes SEPN a Small Cap stock.
SEPTERNA INC (SEPN) currently has 75 employees.
SEPTERNA INC (SEPN) has a support level at 7.11 and a resistance level at 9.85. Check the full technical report for a detailed analysis of SEPN support and resistance levels.
The Revenue of SEPTERNA INC (SEPN) is expected to decline by -49.82% in the next year. Check the estimates tab for more information on the SEPN EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SEPN does not pay a dividend.
SEPTERNA INC (SEPN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.26).
The outstanding short interest for SEPTERNA INC (SEPN) is 7.96% of its float. Check the ownership tab for more information on the SEPN short interest.
ChartMill assigns a technical rating of 5 / 10 to SEPN.
ChartMill assigns a fundamental rating of 3 / 10 to SEPN. No worries on liquidiy or solvency for SEPN as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months SEPN reported a non-GAAP Earnings per Share(EPS) of -7.26. The EPS decreased by -53868.89% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -15.73% | ||
ROE | -17.09% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 80% to SEPN. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 75.79% and a revenue growth -49.82% for SEPN